Press releases.

Maxim – Positive Response Data from INSIGHT-003 in 1L NSCLC; Bodes Well for Ongoing P3 Pivotal TACTI-004 Study – Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)